id: e_cigarette_use_to_NEW:adverse_events_cessation_related
name: E-Cigarette Use â†’ Adverse Events (Cessation-Related)
from_node:
  node_id: e_cigarette_use
  node_name: E-Cigarette Use
to_node:
  node_id: NEW:adverse_events_cessation_related
  node_name: Adverse Events (Cessation-Related)
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: Electronic cigarette use exposes airways to heated aerosol containing nicotine and carrier
  compounds'
- 'Step 2: Short-term irritation of oral and respiratory mucosa occurs'
- 'Step 3: Common transient symptoms include throat/mouth irritation, headache, cough, and nausea'
- 'Step 4: These symptoms tend to dissipate with continued use as tolerance develops'
evidence:
  quality_rating: A
  n_studies: 8
  primary_citation: Nicola Lindson et al. 2025. "Electronic cigarettes for smoking cessation.." https://doi.org/10.1002/14651858.CD010216.pub10
  supporting_citations:
  - 8 studies with 2485 participants reporting adverse events in EC vs behavioral support comparisons
  - 7 studies with 2241 participants in EC vs NRT comparisons for adverse events
  - Additional citations require full-text access
  doi: 10.1002/14651858.CD010216.pub10
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Adverse events may be more common with nicotine EC compared to behavioral support only (RR
  1.22), though evidence is very uncertain. Common AEs include throat/mouth irritation, headache, cough,
  and nausea, which typically resolve with continued use. AE rates are similar between nicotine EC and
  NRT.
quantitative_effects:
  effect_size:
    value: 1.22
    type: relative_risk
    ci_lower: 0.96
    ci_upper: 1.55
  sample_size: 2485
  heterogeneity_i_squared: 66.0
moderators:
- name: comparison_group
  direction: u_shaped
  strength: moderate
  description: AE rates similar to NRT (RR 1.00) but possibly higher than behavioral support alone (RR
    1.22), though evidence uncertain
structural_competency:
  equity_implications: Safety monitoring of novel nicotine products is a regulatory function with equity
    implications. Unregulated or illicit EC products may pose different risk profiles than regulated products
    studied in trials. Access to regulated products vs unregulated alternatives may differ by socioeconomic
    status and geographic location.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.879739'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
